Page last updated: 2024-10-22

amsacrine and Down Syndrome

amsacrine has been researched along with Down Syndrome in 3 studies

Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.

Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)

Research Excerpts

ExcerptRelevanceReference
" Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease."2.72Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. ( de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K, 2006)
"The prognosis for DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of DS acute lymphoblastic leukemia (ALL) is equal to that of non-DS ALL."1.31Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. ( Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM, 2002)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rao, A1
Hills, RK1
Stiller, C1
Gibson, BE1
de Graaf, SS1
Hann, IM1
O'Marcaigh, A1
Wheatley, K1
Webb, DK1
Zwaan, CM1
Kaspers, GJ1
Pieters, R1
Hählen, K1
Janka-Schaub, GE1
van Zantwijk, CH1
Huismans, DR1
de Vries, E1
Rots, MG1
Peters, GJ1
Jansen, G1
Creutzig, U1
Veerman, AJ1
Simon, JH1
Tebbi, CK1
Freeman, AI1
Brecher, ML1
Green, DM1
Sandberg, AA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
ACUTE MYELOID LEUKAEMIA TRIAL 12[NCT00002658]Phase 32,000 participants (Anticipated)Interventional1994-01-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for amsacrine and Down Syndrome

ArticleYear
Acute megakaryoblastic leukemia associated with mosaic Down's syndrome.
    Cancer, 1987, Nov-15, Volume: 60, Issue:10

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 17; Clone Cells;

1987

Trials

1 trial available for amsacrine and Down Syndrome

ArticleYear
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
    British journal of haematology, 2006, Volume: 132, Issue:5

    Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyta

2006

Other Studies

1 other study available for amsacrine and Down Syndrome

ArticleYear
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Blood, 2002, Jan-01, Volume: 99, Issue:1

    Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool;

2002